期刊
SCIENTIFIC REPORTS
卷 11, 期 1, 页码 -出版社
NATURE RESEARCH
DOI: 10.1038/s41598-021-87599-9
关键词
-
资金
- Basic Science Research Program through the National Research Foundation of Korea - Korean government's Ministry of Science and ICT [NRF-2019R1C1C1006672]
- Bio & Medical Technology Development Program through the National Research Foundation of Korea - Korean government's Ministry of Science and ICT [NRF-2016M3A9B6026771]
- Hyundai Motor Chung Mong-Koo Foundation Global Scholarship [FHS-20-008]
Drug resistance is a major cause of therapy failure and cancer relapse. Research has found that EGFR and AXL, two receptor tyrosine kinases, exhibit similar alteration and expression signatures in the context of co-resistance mechanisms between antimitotic drugs and inhibitors of receptor tyrosine kinases.
Drug resistance remains the major culprit of therapy failure in disseminated cancers. Simultaneous resistance to multiple, chemically different drugs feeds this failure resulting in cancer relapse. Here, we investigate co-resistance signatures shared between antimitotic drugs (AMDs) and inhibitors of receptor tyrosine kinases (RTKs) to probe mechanisms of secondary resistance. We map co-resistance ranks in multiple drug pairs and identified a more widespread occurrence of co-resistance to the EGFR-tyrosine kinase inhibitor (TKI) gefitinib in hundreds of cancer cell lines resistant to at least 11 AMDs. By surveying different parameters of genomic alterations, we find that the two RTKs EGFR and AXL displayed similar alteration and expression signatures. Using acquired paclitaxel and epothilone B resistance as first-line AMD failure models, we show that a stable collateral resistance to gefitinib can be relayed by entering a dynamic, drug-tolerant persister state where AXL acts as bypass signal. Delayed AXL degradation rendered this persistence to become stably resistant. We probed this degradation process using a new EGFR-TKI candidate YD and demonstrated that AXL bypass-driven collateral resistance can be suppressed pharmacologically. The findings emphasize that AXL bypass track is employed by chemoresistant cancer cells upon EGFR inhibition to enter a persister state and evolve resistance to EGFR-TKIs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据